Skip to main content
. 2024 May 16;38(7):1522–1533. doi: 10.1038/s41375-024-02278-8

Fig. 3. Cumulative MMR by time point in patients not in MMR at baseline.

Fig. 3

a Cumulative MMR in all evaluable patients (A) overall, (B) by BCR::ABL1IS at baseline, and (C) by prior treatment with ponatinib. IS International Scale, MMR major molecular response. a Treatment discontinuations for any reason were treated as competing events.